Eun Yang
Stock Analyst at Jefferies
(0.51)
# 3,929
Out of 4,855 analysts
43
Total ratings
32%
Success rate
-25.41%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $325.82 | +32.59% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $2.84 | +181.69% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $5.99 | +350.75% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.40 | +279.75% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $38.62 | -14.55% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $2.49 | +1,024.50% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $20.76 | +30.06% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.80 | +288.89% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $4.41 | - | 2 | Jan 9, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $1.69 | +1,379.29% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $0.05 | +150,200.60% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $84 | $127.85 | -34.30% | 3 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.35 | +1,751.85% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.20 | - | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $11.92 | +193.62% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $290.33 | -24.22% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $38 → $31 | $29.61 | +4.69% | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $133.13 | +132.86% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $112.46 | -28.86% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $325.82
Upside: +32.59%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $2.84
Upside: +181.69%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $5.99
Upside: +350.75%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.40
Upside: +279.75%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $38.62
Upside: -14.55%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $2.49
Upside: +1,024.50%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $20.76
Upside: +30.06%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.80
Upside: +288.89%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $4.41
Upside: -
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $1.69
Upside: +1,379.29%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $0.05
Upside: +150,200.60%
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $127.85
Upside: -34.30%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.35
Upside: +1,751.85%
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $6.20
Upside: -
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $11.92
Upside: +193.62%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $290.33
Upside: -24.22%
Nov 3, 2017
Maintains: Hold
Price Target: $38 → $31
Current: $29.61
Upside: +4.69%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $133.13
Upside: +132.86%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $112.46
Upside: -28.86%